News headlines about Heron Therapeutics (NASDAQ:HRTX) have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Heron Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.6362457665679 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s analysis:

A number of research analysts have recently weighed in on the company. Cowen and Company reissued a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a report on Friday, May 26th. ValuEngine raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Heron Therapeutics in a report on Monday, June 26th. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Wednesday, July 12th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $26.00 price objective on shares of Heron Therapeutics in a report on Friday, July 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $29.25.

Shares of Heron Therapeutics (HRTX) opened at 15.20 on Tuesday. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85. The firm’s market capitalization is $822.90 million. The company’s 50-day moving average price is $15.84 and its 200 day moving average price is $14.97.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. On average, equities research analysts forecast that Heron Therapeutics will post ($3.51) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/18/heron-therapeutics-hrtx-earning-somewhat-positive-news-coverage-accern-reports.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Insider Buying and Selling by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.